Fusion peptides from oncogenic chimeric proteins as putative specific biomarkers of cancer

Molecular and Cellular Proteomics

Volumn 12, Issue 10, 2013, Pages 2714-2723

  Conlon, Kevin P ^a   Basrur, Venkatesha ^a   Rolland, Delphine ^a   Wolfe, Thomas ^a   Nesvizhskii, Alexey I ^a   MacCoss, Michael J ^b   Lim, Megan S ^a   Elenitoba Johnson, Kojo S J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANAPLASTIC LYMPHOMA KINASE; APOPTOSIS INHIBITOR 2; APOPTOSIS INHIBITOR 2 MUCOSA ASSOCIATED LYMPHOID TISSUE; BIOLOGICAL MARKER; BREAKPOINT CLUSTER REGION PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN ABELSON KINASE; CHIMERIC PROTEIN; HYBRID PROTEIN; NUCLEOPHOSMIN; NUCLEOPHOSMIN ANAPLASTIC LYMPHOMA KINASE; STABLE ISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CELL LYSATE; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FUSION PEPTIDE MULTIPLE REACTION MONITORING MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LYMPHOMA; LYMPHOMA CELL LINE; MARGINAL ZONE LYMPHOMA; MASS SPECTROMETER; MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

CELL LINE, TUMOR; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MASS SPECTROMETRY; ONCOGENE PROTEINS, FUSION; PEPTIDES; PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84885170368     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M113.029926     Document Type: Article

References (17)

1. Rowley, J. D. (2001) Chromosome translocations: dangerous liaisons revisited. Nat. Rev. Cancer 1, 245-250
2. Stratton, M. R., Campbell, P. J., and Futreal, P. A. (2009) The cancer genome. Nature 458, 719-724
3. Mitelman, F., Johansson, B., and Mertens, F. (2007) The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233-245
4. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566
5. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037
6. Kwak, E. L., Bang, Y. J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. H., Dezube, B. J., Janne, P. A., Costa, D. B., Varella-Garcia, M., Kim, W. H., Lynch, T. J., Fidias, P., Stubbs, H., Engelman, J. A., Sequist, L. V., Tan, W., Gandhi, L., Mino-Kenudson, M., Wei, G. C., Shreeve, S. M., Ratain, M. J., Settleman, J., Christensen, J. G., Haber, D. A., Wilner, K., Salgia, R., Shapiro, G. I., Clark, J. W., and Iafrate, A. J. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703
7. Domon, B., and Aebersold, R. (2006) Mass spectrometry and protein analysis. Science 312, 212-217
8. Yates, J. R., Ruse, C. I., and Nakorchevsky, A. (2009) Proteomics by mass spectrometry: approaches, advances, and applications. Annu. Rev. Biomed. Eng. 11, 49-79
9. Picotti, P., and Aebersold, R. (2012) Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat. Methods 9, 555-566
10. Anderson, L., and Hunter, C. L. (2006) Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 5, 573-588
11. Keshishian, H., Addona, T., Burgess, M., Kuhn, E., and Carr, S. A. (2007) Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 6, 2212-2229
12. Geoghegan, K. F., Hoth, L. R., Tan, D. H., Borzilleri, K. A., Withka, J. M., and Boyd, J. G. (2002) Cyclization of N-terminal S-carbamoylmethylcysteine causing loss of 17 Da from peptides and extra peaks in peptide maps. J. Proteome Res. 1, 181-187
13. Keshishian, H., Addona, T., Burgess, M., Mani, D. R., Shi, X., Kuhn, E., Sabatine, M. S., Gerszten, R. E., and Carr, S. A. (2009) Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 8, 2339-2349
14. Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., and Look, A. T. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284
15. Carr, S. A., and Anderson, L. (2008) Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? Clin. Chem. 54, 1749-1752
16. Wang, Q., Chaerkady, R., Wu, J., Hwang, H. J., Papadopoulos, N., Kopelovich, L., Maitra, A., Matthaei, H., Eshleman, J. R., Hruban, R. H., Kinzler, K. W., Pandey, A., and Vogelstein, B. (2011) Mutant proteins as cancer-specific biomarkers. Proc. Natl. Acad. Sci. U. S. A. 108, 2444-2449
17. Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J., Jackson, A. M., Hardie, D. B., Anderson, N. L., and Borchers, C. H. (2009) Multiple reaction monitoringbased, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics 8, 1860-1877